Evidence map›Paper›PMID 42256331›Full record

ArticleIJU case reports2026

Significant Response to Nivolumab Plus Ipilimumab in Metastatic Mucinous Tubular and Spindle Cell Carcinoma: A Case Report.

Sho Shimasaki, Shinkuro Yamamoto, Mitsuko Iguchi, Erika Yamashita, Kaya Atagi, Yuhei Shiba, Satoshi Fukata, Hirofumi Satake, Takashi Karashima, Keiji Inoue

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJU case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sho ShimasakiDepartment of Urology Kochi Medical School, Kochi University Nankoku Kochi Japan.
Shinkuro YamamotoDepartment of Urology Kochi Medical School, Kochi University Nankoku Kochi Japan.ORCID https://orcid.org/0000-0002-3620-7666
Mitsuko IguchiDepartment of Diagnostic Pathology Kochi Medical School, Kochi University Nankoku Kochi Japan.
Erika YamashitaDepartment of Urology Kochi Medical School, Kochi University Nankoku Kochi Japan.
Kaya AtagiDepartment of Urology Kochi Medical School, Kochi University Nankoku Kochi Japan.
Yuhei ShibaDepartment of Urology Chikamori Hospital Kochi Kochi Japan.
Satoshi FukataDepartment of Urology Kochi Medical School, Kochi University Nankoku Kochi Japan.
Hirofumi SatakeDepartment of Urology Chikamori Hospital Kochi Kochi Japan.
Takashi KarashimaDepartment of Urology Kochi Prefectural Aki General Hospital Aki Kochi Japan.
Keiji InoueDepartment of Urology Kochi Medical School, Kochi University Nankoku Kochi Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare renal cell carcinoma subtype that is typically indolent but may exhibit aggressive behavior. No standard systemic therapy has been established for metastatic MTSCC. Case Presentation: A 71-year-old woman underwent retroperitoneoscopic radical left nephrectomy for MTSCC (pT1b). Six months later, computed tomography (CT) and Conclusion: This case demonstrates the potential efficacy of combination immunotherapy in aggressive metastatic MTSCC.

Indexed as

immune checkpoint inhibitoripilimumabmucinous tubular and spindle cell carcinomanivolumabrenal cell carcinoma

Identifiers

PMID42256331
PMCPMC13240087

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.